Queen’s University Belfast (QUB) is taking part in a UK-wide trial to investigate whether a drug normally used to treat high blood pressure could also slow down the progression of Alzheimer’s Disease (AD).
The multi-centre clinical trial is being led by the University of Bristol in partnership with Queen’s University, University of Cambridge and the University of London with funding from the National Institute for Health Research (NIHR) and Medical Research Council (MRC) Efficacy and Mechanism Evaluation (EME) programme. The trial known as RADAR (Reducing pathology in Alzheimer’s Disease through Angiotensin taRgeting), is hoping to recruit approximately 230 participants across the UK including at least 10 in Northern Ireland, together with a similar number of carers.
The study is being lead in Northern Ireland by Dr Bernadette McGuinness and Prof Peter Passmore and will be supported by the Northern Ireland Clinical Research Network. The researchers also plan to use Join Dementia Research to help with recruitment to the study.
Click here for the full story from the QUB website